Tierarztl Prax Ausg G Grosstiere Nutztiere 2006; 34(05): 281-288
DOI: 10.1055/s-0037-1621081
Wiederkäuer
Schattauer GmbH

Vaccination against BVD/MD: Direct comparison of different vaccines and vaccination strategies

Article in several languages: deutsch | English
M. König
1   Aus dem Institut für Virologie (Leiter: Prof. Dr. H.-J. Thiel), FB Veterinärmedizin, JLU Gießen
,
L. Jöns-Anders
2   der Klinik für Klauentiere (Leiterin: Prof. Dr. K. Müller), FB Veterinärmedizin, FU Berlin
,
Ch. Förster
1   Aus dem Institut für Virologie (Leiter: Prof. Dr. H.-J. Thiel), FB Veterinärmedizin, JLU Gießen
,
K. Fading
3   und der Arbeitsgruppe Biomathematik und Datenverarbeitung (Leiter: Dr. K. Failing), FB Veterinärmedizin, JLU Gießen
,
H.-P. Heckert
2   der Klinik für Klauentiere (Leiterin: Prof. Dr. K. Müller), FB Veterinärmedizin, FU Berlin
,
H.-J. Thiel
1   Aus dem Institut für Virologie (Leiter: Prof. Dr. H.-J. Thiel), FB Veterinärmedizin, JLU Gießen
› Author Affiliations
Further Information

Publication History

Eingegangen: 29 December 2005

akzeptiert: 13 February 2006

Publication Date:
10 January 2018 (online)

Preview

Summary:

Objective: Bovine viral diarrhoea/mucosal disease (BVD/MD) is still regarded as one of the economically most important viral infections of cattle. Due to the high prevalence and the geographical situation in Germany it is widelyaccepted that vaccination against BVD/MD is currently indispensable. A key issue in this regard is the protection againstdiaplacentaltransmission of the virus. A number of vaccines based on replication competent virus (“live vaccines”) or inactivated virus (“killed vaccines”) have been registered in Germany; some with the indication “fetal protection”. In addition to the exclusive use of “live”- or “killed vaccines”, both types of vaccines canbe combined in the so called biphasic vaccination scheme. The objective of the current report was to compare different vaccines and vaccination schemes. Material and methods: Using different vaccines, a total of 60 cattle were vaccinated against BVD/MD. Serum samples were obtained over a period of 10 months and tested in a neutralization assay against three BVD test viruses from the groups BVDV-1a, -1b and BVDV-2a. Results: Two injections of a new inactivated vaccine (PregSure® BVD) induced high titres of neutralizing antibodies against BVDV-1 comparable to titres observed afterthe combination of inactivated and “live vaccines” in the biphasic vaccination scheme. With regard to BVDV-2 PregSure® BVD ledto even higherantibody titres. Conclusions: The newinactivated vaccine PregSure® BVD is also suited for use in biphasic vaccination schemes. Clinical relevance: The exclusive use of “killed vaccines” has practical advantages. The main objective of all vaccinations against BVD/MD remains “fetal protection”.